These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Hubbard RC; Crystal RG Lung; 1990; 168 Suppl():565-78. PubMed ID: 2117165 [TBL] [Abstract][Full Text] [Related]
46. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. Stocks JM; Brantly M; Pollock D; Barker A; Kueppers F; Strange C; Donohue JF; Sandhaus R COPD; 2006 Mar; 3(1):17-23. PubMed ID: 17175661 [TBL] [Abstract][Full Text] [Related]
47. Phenotypes and serum level of alpha-1-antitrypsin in lung cancer. Topic A; Ljujic M; Petrovic-Stanojevic N; Dopudja-Pantic V; Radojkovic D J BUON; 2011; 16(4):672-6. PubMed ID: 22331720 [TBL] [Abstract][Full Text] [Related]
48. Serum levels and genotype distribution of α1-antitrypsin in the general population. Ferrarotti I; Thun GA; Zorzetto M; Ottaviani S; Imboden M; Schindler C; von Eckardstein A; Rohrer L; Rochat T; Russi EW; Probst-Hensch NM; Luisetti M Thorax; 2012 Aug; 67(8):669-74. PubMed ID: 22426792 [TBL] [Abstract][Full Text] [Related]
50. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation. Ma S; Lin YY; He J; Rouhani FN; Brantly M; Turino GM COPD; 2013 Aug; 10(4):473-81. PubMed ID: 23560990 [TBL] [Abstract][Full Text] [Related]
51. The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients. Schouten IGM; Mumford RA; Moes DJAR; Hiemstra PS; Stolk J Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360796 [TBL] [Abstract][Full Text] [Related]
52. Danazol-induced augmentation of serum alpha 1-antitrypsin levels in individuals with marked deficiency of this antiprotease. Gadek JE; Fulmer JD; Gelfand JA; Frank MM; Petty TL; Crystal RG J Clin Invest; 1980 Jul; 66(1):82-87. PubMed ID: 6967489 [TBL] [Abstract][Full Text] [Related]
53. [Alpha-1-antitrypsin deficiency - an update]. Bernhard N; Bals R; Fähndrich S Dtsch Med Wochenschr; 2016 Sep; 141(20):1467-1469. PubMed ID: 27701692 [TBL] [Abstract][Full Text] [Related]
54. Historical role of alpha-1-antitrypsin deficiency in respiratory and hepatic complications. Zuo L; Pannell BK; Zhou T; Chuang CC Gene; 2016 Sep; 589(2):118-22. PubMed ID: 26768576 [TBL] [Abstract][Full Text] [Related]
55. Alpha-1 Antitrypsin Deficiency in COPD Patients: A Cross-Sectional Study. Sorroche PB; Fernández Acquier M; López Jove O; Giugno E; Pace S; Livellara B; Legal S; Oyhamburu J; Saez MS Arch Bronconeumol; 2015 Nov; 51(11):539-43. PubMed ID: 25800328 [TBL] [Abstract][Full Text] [Related]
56. The direct medical costs of alpha(1)-antitrypsin deficiency. Mullins CD; Huang X; Merchant S; Stoller JK; Chest; 2001 Mar; 119(3):745-52. PubMed ID: 11243952 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Stocks JM; Brantly ML; Wang-Smith L; Campos MA; Chapman KR; Kueppers F; Sandhaus RA; Strange C; Turino G BMC Clin Pharmacol; 2010 Sep; 10():13. PubMed ID: 20920295 [TBL] [Abstract][Full Text] [Related]
58. Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. Carroll TP; Greene CM; O'Connor CA; Nolan AM; O'Neill SJ; McElvaney NG J Immunol; 2010 Apr; 184(8):4538-46. PubMed ID: 20228200 [TBL] [Abstract][Full Text] [Related]